Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Phase of Epilepsy Research Using DehydraTECH(TM)-CBD
Lexaria’s patented DehydraTECH(TM) technology provides faster delivery times, increases bioavailability, increases brain absorption, improves drug potency, reduces administration costs, and masks unwanted flavorsThe epilepsy research will compare the FDA-approved Epidiolex(R) to the company’s proprietary DehydraTECH-CBD formulationThe global cannabidiol (“CBD”) market had an estimated value of $2.7 billion in 2021 and is expected to reach $111.8 billion by 2030, driven by an increase in demand for…